Six surprisingly hopeful advances in battle against dementia

LONDON: In autumn 2019, the mood within the field of dementia research was bleak. Multiple late-stage clinical trials had ended in dismal failure, prompting six of the world’s leading pharmaceutical companies to announce that they were pulling their neuroscience research and development programs indefinitely. Executives cited escalating costs and declared that the likelihood of finding effective treatments for Alzheimer’s and other dementias was remote.

Now, just six years on, that nadir feels like a distant memory. The past three years have yielded the first disease-modifying drugs for Alzheimer’s in the shape of the plaque-removing antibodies lecanemab and donanemab. There have also been unexpected and potentially game-changing breakthroughs such as a new gene therapy for Huntington’s disease, itself a form of dementia, which could usher in novel treatments for other dementias. At the same time, our understanding of how lifestyle measures can prevent, delay and slow dementia continues to advance.

All in all, experts agree that there is now more cause for hope than at any point in recent memory. “I am optimistic on two levels,” says Bruce Yankner, professor of genetics and neurology at Harvard Medical School. “Firstly, the technology for addressing the basic causes and treatment of Alzheimer’s disease has really taken off. We also have the first blood biomarkers of the disease, and that’s very important for preventative treatment, trials and so on.”

With that in mind, here are the six reasons why there is more reason for optimism in the battle against dementia.

1. We can limit side effects of treatment

One of the reasons dementia drugs lecanemab and donanemab have been shown to have an effect on slowing down the progression of Alzheimer’s is that they remove a toxic form of the amyloid protein from the brain, which is contributing to the death of neurons.

Research shows that one of the keys to delaying the disease is not just removing the amyloid but doing so as swiftly as possible. Because of this, there is considerable anticipation surrounding a next-generation antibody-based drug called remternetug, the subject of a recent Phase 3 trial (the final step in drug development), for which the results are expected to be published in the spring.

“One of the things we’ve learned is that it’s not how much amyloid you can remove, but how quickly you can get it down to a certain level,” says Richard Oakley, associate director of research and innovation at the Alzheimer’s Society. “Remternetug targets the same form of amyloid as donanemab, but what we know from the early data on remternetug is that 75 per cent of people cleared that amyloid within just six months of treatment. Clearing the same amount of amyloid took 18 months on donanemab, so this new drug appears to remove it much more efficiently.”

While lecanemab and donanemab helped initiate a surge of new hope for Alzheimer’s disease, they came with distinct limitations, in particular a heightened risk of dangerous microbleeds and swelling in the brain. To keep tabs on this and ensure patient safety, treatment comes with the requirement for regular and costly MRI scans, one of the main reasons NICE ultimately decided that neither drug provided enough benefit to justify the cost of making it available on the NHS.

Another new amyloid-removing antibody called trontinemab, which is also being assessed in Phase 3 trials, could be safer and more cost effective to roll out, however, because it can be delivered in much smaller doses. This is because it uses a “Brainshuttle” technology which sees it piggyback onto another molecule which is naturally more effective at crossing the blood-brain barrier and accessing the brain. “It enables much lower concentrations of drug to be given to the individual, while still getting a large amount of drug into the brain,” says Oakley.

All of this still needs to be proved in the form of hard scientific data, but researchers are also exploring formulations which would allow various antibody drugs to be injected subcutaneously, rather than requiring hospital visits for intravenous infusions. Oakley says this raises the possibility that, in the future, they could even be given to patients in their own homes. “That would make a massive difference to people’s quality of life,” he says.

2. New drugs are in development

While most of the drugs so far have been focused on targeting amyloid, researchers believe that stopping Alzheimer’s and other dementias in their tracks will require combination therapy, a little like the cocktail of drugs used to target certain cancers or HIV.

A study published last year identified 182 clinical trials taking place around the world assessing 138 different drugs for Alzheimer’s. Oakley points out that a number of the therapeutics in early-stage trials are targeting other key disease mechanisms driving Alzheimer’s. They include drugs attempting to remove a toxic form of the tau protein which accumulates inside neurons and disrupts their ability to obtain nutrients, to other medications aimed at dampening inflammation, or improving blood flow to the brain.

“Restricted blood flow into the brain can lead to so-called necrotic environments that are bad for your brain cells,” says Oakley. “So there’s a lot of interest at the moment in repurposing drugs from cardiovascular disease into dementia to see if they can play a role.”

3. We can spot and treat Alzheimer’s earlier

A newly released study has found that measuring the levels of p-tau217 in the blood – a protein which reflects the amount of toxic tau in the brain – can both assess a person’s risk of developing Alzheimer’s and predict when they might start developing signs of cognitive problems.

This may sound terrifying, but it could soon play a critical role in allowing people to stay cognitively normal for longer. All the evidence to date indicates that antibody drugs work best when given to people early in the disease course and, according to Oakley, mathematical models suggest that if the drugs could be given to people who are going to get Alzheimer’s but have not yet become symptomatic, it may be possible to slow the disease to an even greater extent.

“The trials indicated that lecanemab and donanemab can slow disease by six months on average,” he says. “Real-world data is now showing that if you give them earlier, it slows the disease by 12 to 18 months, which is really great. And modelling suggests that if you could give them even earlier, it might slow the disease by many years.”

And if blood tests indicate someone is at a high risk of getting Alzheimer’s, it might also be possible to administer a vaccine which attempts to delay the onset of the disease by preventing the further accumulation of toxic proteins in the brain.

4. New gene therapies are in development

In September, scientists at University College London unveiled the results of a landmark gene therapy trial for Huntington’s disease, a dementia caused by an inherited gene mutation which leads to cognitive and physical decline, often beginning in a person’s 30s or 40s.

The new therapy, which attempts to mitigate some of the consequences of this mutation by inserting replacement chunks of DNA into the cells of the striatum – the part of the brain where the disease develops – appeared to slow disease progression by 75 per cent after three years.

According to Yankner, gene therapy could have potential for other dementias. For example, genetic studies have found that people who carry two E4 variants of the apolipoprotein E (APOE) gene, which is around two to three percent of the UK population, are highly likely to develop Alzheimer’s eventually.

But, as with Huntington’s, it may soon be feasible to intervene, for example through inserting the E2 variant of the APOE gene, which is known to have protective effects against Alzheimer’s, into brain cells. Studies in mice have already indicated that this could reduce both the accumulation of toxic amyloid proteins and brain inflammation, as well as appearing to reduce signs of neurodegeneration.

“Putting the E2 form of the gene in the brain to see if it can counteract the deleterious effect of the E4 variant, I think that’s a promising avenue,” says Yankner. “And there’s a real need because these people with two E4s have also been shown to be at a higher risk of brain bleeds when you give them antibody immunotherapies to remove amyloid. So you have this substantial population that’s ineligible for these new therapies.”

5. We understand more on how lifestyle can improve brain health

Numerous studies have indicated the value of wearing hearing aids to manage waning auditory abilities, maintaining muscle strength in middle to later life, consuming a brain-healthy diet and doing cognitively stimulating activities such as strategy games for maintaining your faculties.

Now, a major US study called POINTER has highlighted that if you’re becoming worried about your cognitive health, it’s possible to change that trajectory. The trial took more than 2,000 Americans, aged 60-79, who were deemed to be at high risk of cognitive decline and dementia and put them on a two-year lifestyle intervention regime.

It consisted of a MIND diet, a rigorous weekly exercise regime (consisting of four days of aerobic exercise, two days of resistance training and two days of stretching and balance exercises), as well as cognitive exercises three times a week. By the end of the trial, the participants’ cognition had markedly improved.

6. We’re discovering new ways of preventing cognitive decline

Research is also steadily pointing to new ways of preventing cognitive decline, for example through midlife vaccines which may not only protect you from damaging viruses which could affect your brain but could also boost the body’s wider immune response, stimulating white blood cells to enter your brain and cleanse it more effectively of toxic proteins.

One study observed that receiving an annual flu vaccine for three years in a row seems to lower your risk of getting dementia by 20 per cent during the ensuing four to eight years, while receiving two doses a year reduces your risk by 40 per cent. Last year, a Stanford University study which used electronic health records from 280,000 older adults in Wales found that those who were vaccinated against shingles were 20 per cent less likely to develop dementia during the following seven years.

Yankner is interested in an emerging theory relating to the metal lithium which appears to be capable of playing a protective role in brain health by maintaining healthy neuron function. His own research in mice has found that the formation of amyloid plaques traps lithium, making it less effective, but giving the rodents supplements of a particular form of lithium named lithium orotate could reverse the signs of disease.